121,539 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Man Group plc

Man Group plc purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 121,539 shares of the company's stock, valued at approximately $1,607,000. Man Group plc owned about 0.14% of Syndax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of SNDX. Barclays PLC increased its position in Syndax Pharmaceuticals by 143.4% in the third quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after purchasing an additional 110,535 shares during the last quarter. Inspire Investing LLC raised its stake in shares of Syndax Pharmaceuticals by 44.5% in the fourth quarter. Inspire Investing LLC now owns 30,792 shares of the company's stock valued at $407,000 after acquiring an additional 9,484 shares during the period. KBC Group NV lifted its holdings in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after acquiring an additional 3,559 shares during the last quarter. R Squared Ltd purchased a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $26,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after purchasing an additional 1,732 shares during the period.

Syndax Pharmaceuticals Trading Up 0.8%

Shares of SNDX traded up $0.08 during mid-day trading on Tuesday, hitting $9.93. The company's stock had a trading volume of 2,805,374 shares, compared to its average volume of 1,778,700. The company's 50-day moving average is $11.76 and its 200-day moving average is $13.61. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $25.07. The firm has a market capitalization of $854.45 million, a price-to-earnings ratio of -2.74 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. The business's quarterly revenue was up 1900.0% on a year-over-year basis. During the same period last year, the firm earned ($0.85) EPS. As a group, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SNDX. HC Wainwright reissued a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Scotiabank increased their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Finally, Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).